マーケットレポート詳細

創傷ケア用バイオ医薬品の世界市場:製品別、創傷タイプ別2027年予測

Wound Care Biologics Market by Product (Biological Skin Substitutes, Topical Agents), Wound Type (Ulcers [Diabetic Foot, Venous, Pressure Ulcers], Surgical & Traumatic Wounds, Burns), End User (Hospitals, ASCs, Burn Centers) – Global Forecast to 2027

出版元:MarketsandMarkets   出版元について
発行年:2022年6月
定価 :Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文174ページになります。
商品コード:MAM2957

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。

【レポート紹介】

創傷ケア用バイオ医薬品の世界市場規模は2022年で18億ドル、2027年に24億ドル、市場の平均年成長率は5.4%で推移する見込みです。
レポートは創傷ケア用バイオ医薬品の世界市場について2027年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測(製品別市場、創傷タイプ別市場、等)を中心に構成されています。また競合状況、主要企業情報(12社)、COVID-19の影響、市場シェア分析、競合状況などの分析も加味し、創傷ケア用バイオ医薬品市場の動向および今後成長性を詳細にレポートしています。

【レポート構成概要】

◆創傷ケア用バイオ医薬品の世界市場予測2017-2027年

・市場規模(US$)

◆製品別、市場-2027年

皮膚代用品
・ヒトドナー組織由来製品
・無細胞系動物由来製品
・生合成製品
外用剤
※(市場規模US$)

◆創傷タイプ別、市場-2027年

潰瘍
・糖尿病性足潰瘍
・静脈潰瘍
・褥瘡
・その他潰瘍
手術/外傷
火傷
※(市場規模US$)

◆エンドユーザー別、市場-2027年

・病院
・外来手術センター
・火傷治療センター/創傷クリニック
※(市場規模US$)

◆主要国地域別市場-2027年

北米
・米国、カナダ
欧州
・英国、ドイツ、フランス
・その他欧州
アジア太平洋
・日本、中国、インド
・その他アジア太平洋
中南米
中東アフリカ
※地域別に全セグメントの細分化データ掲載
※国別に製品大分類別、創傷タイプ大分類別、エンドユーザー別の細分化データ掲載、詳細は目次参照

◆市場分析

・市場ダイナミクス(ドライバー、障壁、機会)
・COVID-19の影響
・市場シェア分析
・競合状況

◆創傷ケア用バイオ医薬品の主要企業プロフィール動向

・SMITH & NEPHEW PLC
・ORGANOGENESIS INC.
・MIMEDX
・INTEGRA LIFESCIENCES
・STRYKER CORPORATION
・MÖLNLYCKE HEALTH CARE AB
・VERICEL CORPORATION
・ANIKA THERAPEUTICS, INC.
・BIOVENTUS LLC
・ABBVIE INC.
・KERECIS
・MARINE POLYMER TECHNOLOGIES, INC.

(その他企業)
・MERAKRIS THERAPEUTICS
・POLYMEDICS INNOVATIONS GMBH
・FIBROHEAL WOUNDCARE PVT. LTD.
・ANAMAY BIOTECH, INC.
・VIRCHOW BIOTECH PRIVATE LIMITED
・MEDLINE INDUSTRIES, LP
・TIDES MEDICAL
・VISCUS BIOLOGICS LLC
・STABILITY BIOLOGICS
・MTF BIOLOGICS
・SKYE BIOLOGICS HOLDINGS, LLC
・ALLOSOURCE
・SURGILOGIX
(全174頁)


【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次)

1      INTRODUCTION

1.1             OBJECTIVES OF THE STUDY
1.2             MARKET DEFINITION
1.2.1              INCLUSIONS AND EXCLUSIONS OF THE STUDY
1.2.2              MARKETS COVERED   28
・     FIGURE 1            WOUND CARE BIOLOGICS MARKET
1.2.3              YEARS CONSIDERED FOR THE STUDY
1.3             CURRENCY
1.4             LIMITATIONS
1.5             STAKEHOLDERS
1.6             SUMMARY OF CHANGES

2      RESEARCH METHODOLOGY

2.1             RESEARCH DATA
2.2             RESEARCH APPROACH
・     FIGURE 2            WOUND CARE BIOLOGICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1              SECONDARY DATA
2.2.1.1            KEY DATA FROM SECONDARY SOURCES
2.2.2              PRIMARY DATA
2.2.2.1            PRIMARY SOURCES
2.2.2.2            KEY DATA FROM PRIMARY SOURCES
2.2.2.3            KEY INDUSTRY INSIGHTS
・     FIGURE 3            BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION
2.3             MARKET SIZE ESTIMATION
2.3.1              BOTTOM-UP APPROACH
2.3.1.1            APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH
・     FIGURE 4            BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2            APPROACH 3: PRESENTATIONS OF COMPANIES AND PRIMARY INTERVIEWS
2.3.1.3            GROWTH FORECAST
2.3.1.4            CAGR PROJECTIONS
・     FIGURE 5            CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2              TOP-DOWN APPROACH   38
・     FIGURE 6            WOUND CARE BIOLOGICS MARKET: TOP-DOWN APPROACH
2.4             MARKET BREAKDOWN AND DATA TRIANGULATION
・     FIGURE 7            DATA TRIANGULATION METHODOLOGY
2.5             MARKET SHARE
2.6             ASSUMPTIONS FOR THE STUDY

3      EXECUTIVE SUMMARY

・     FIGURE 8            WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 
2022 VS. 2027 (USD MILLION)
・     FIGURE 9            WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 
2022 VS. 2027 (USD MILLION)
・     FIGURE 10          WOUND CARE BIOLOGICS MARKET, BY END USER, 
2022 VS. 2027 (USD MILLION)
・     FIGURE 11          WOUND CARE BIOLOGICS MARKET, BY REGION,
2022 VS. 2027 (USD MILLION)

4      PREMIUM INSIGHTS

4.1             WOUND CARE BIOLOGICS MARKET OVERVIEW
・     FIGURE 12          INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET FOR WOUND CARE BIOLOGICS
4.2             WOUND CARE BIOLOGICS MARKET SHARE, BY PRODUCT,  2022 VS. 2027
・     FIGURE 13          BIOLOGICAL SKIN SUBSTITUTES WILL CONTINUE TO DOMINATE MARKET IN 2027
4.3             WOUND CARE BIOLOGICS MARKET SHARE, BY WOUND TYPE, 2022 VS. 2027
・     FIGURE 14          ULCERS SEGMENT DOMINATES MARKET
4.4             WOUND CARE BIOLOGICS MARKET SHARE, BY END USER,  2022 VS. 2027
・     FIGURE 15          HOSPITALS ARE LARGEST END USERS OF WOUND CARE BIOLOGICS
4.5             WOUND CARE BIOLOGICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
・     FIGURE 16          ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN WOUND CARE BIOLOGICS MARKET DURING FORECAST PERIOD

5      MARKET OVERVIEW

5.1             INTRODUCTION
5.2             MARKET DYNAMICS
・     FIGURE 17          WOUND CARE BIOLOGICS MARKET: DRIVERS, RESTRAINTS,  AND OPPORTUNITIES
5.2.1              DRIVERS
5.2.1.1            GROWING PREVALENCE OF DISEASES & CONDITIONS AFFECTING WOUND HEALING CAPABILITIES
5.2.1.1.1            GROWING GERIATRIC POPULATION
5.2.1.1.2            INCREASING PREVALENCE OF DIABETES AND TARGET CONDITIONS
・     FIGURE 18          PREVALENCE OF DIABETES IN ADULTS (20–79 YEARS), BY REGION, 
2021 VS. 2045 (MILLION CASES)
・     TABLE 1              TOTAL HEALTH EXPENDITURE (USD) DUE TO DIABETES (20–79 YEARS) IN 2021, BY COUNTRY
・     TABLE 2              LIST OF COMMERCIALLY AVAILABLE SKIN SUBSTITUTES, THEIR INDICATIONS, AND SUPPORTING EVIDENCE FOR USE IN CHRONIC WOUNDS
5.2.1.1.3            INCREASING NUMBER OF SURGICAL PROCEDURES ACROSS THE GLOBE
5.2.1.1.4            INCREASING NUMBER OF TRAUMATIC WOUNDS
・     TABLE 3              PREVALENCE OF ROAD ACCIDENTS
5.2.1.2            INCREASING INCIDENCE OF BURN INJURIES
5.2.1.3            INNOVATIONS IN WOUND CARE BIOLOGICS
5.2.2              MARKET RESTRAINTS   52
5.2.2.1            HIGH COST OF WOUND CARE BIOLOGIC PRODUCTS
・     TABLE 4              AVERAGE COST OF TREATMENT FOR DIABETIC FOOT ULCERS (2018)
5.2.2.2            RISK OF SKIN SUBSTITUTE FAILURE
・     TABLE 5              COMPARISON OF OUTCOMES (STSG VS. FTSG PATIENTS)
5.2.3              OPPORTUNITIES
5.2.3.1            GROWTH POTENTIAL OF EMERGING ECONOMIES
・     TABLE 6              STRATEGIC DEVELOPMENTS IN THE ASIA PACIFIC
5.2.3.2            3D SKIN PRINTING
5.3             IMPACT OF COVID-19 ON THE WOUND CARE BIOLOGICS MARKET

6      WOUND CARE BIOLOGICS MARKET, BY PRODUCT

6.1             INTRODUCTION
・     TABLE 7              WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・     TABLE 8              WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
6.2             BIOLOGICAL SKIN SUBSTITUTES
・     TABLE 9              KEY PRODUCTS IN THE BIOLOGICAL SKIN SUBSTITUTES MARKET
・     TABLE 10            WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2017–2020 (USD MILLION)
・     TABLE 11            WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2021–2027 (USD MILLION)
・     TABLE 12            WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY TYPE,  2017–2020 (USD MILLION)
・     TABLE 13            WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY TYPE,  2021–2027 (USD MILLION)
6.2.1              HUMAN DONOR TISSUE-DERIVED PRODUCTS
6.2.1.1            HIGH EFFICACY OF HUMAN DONOR TISSUE-DERIVED PRODUCTS TO SUPPORT MARKET DEMAND
・     TABLE 14            KEY PRODUCTS IN THE HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET
・     TABLE 15            HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET, BY REGION, 
2017–2020 (USD MILLION)
・     TABLE 16            HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET, BY REGION, 
2021–2027 (USD MILLION)
6.2.2              ACELLULAR ANIMAL-DERIVED PRODUCTS
6.2.2.1            RECOGNITION OF THE IMPORTANCE OF ECM IN WOUND TREATMENT HAS LED TO THE DEVELOPMENT OF ACELLULAR WOUND CARE BIOLOGICS
・     TABLE 17            KEY PRODUCTS IN THE ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET
・     TABLE 18            ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET, BY REGION, 
2017–2020 (USD MILLION)
・     TABLE 19            ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET, BY REGION, 
2021–2027 (USD MILLION)
6.2.3              BIOSYNTHETIC PRODUCTS
6.2.3.1            INCREASED BIOBURDEN OF INFECTED WOUNDS TO STIMULATE MARKET GROWTH   64
・     TABLE 20            BIOSYNTHETIC PRODUCTS MARKET, BY REGION, 2017–2020 (USD MILLION)
・     TABLE 21            BIOSYNTHETIC PRODUCTS MARKET, BY REGION, 2021–2027 (USD MILLION)
6.3             TOPICAL AGENTS
6.3.1              INCREASE IN THE NUMBER OF CHRONIC ULCERS OVER THE LAST FEW YEARS TO PROPEL MARKET GROWTH
・     TABLE 22            WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION,  2017–2020 (USD MILLION)
・     TABLE 23            WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION,  2021–2027 (USD MILLION)

7      WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE

7.1             INTRODUCTION
・     TABLE 24            WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・     TABLE 25            WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
7.1.1              PRIMARY NOTES
7.1.1.1            KEY INDUSTRY INSIGHTS
7.2             ULCERS
・     TABLE 26            WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY REGION,
2017–2020 (USD MILLION)
・     TABLE 27            WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY REGION,
2021–2027 (USD MILLION)
・     TABLE 28            WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY TYPE,
2017–2020 (USD MILLION)
・     TABLE 29            WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY TYPE,
2021–2027 (USD MILLION)
7.2.1              DIABETIC FOOT ULCERS
7.2.1.1            INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET GROWTH
・     TABLE 30            WOUND CARE BIOLOGICS MARKET FOR DIABETIC FOOT ULCERS, BY REGION,  2017–2020 (USD MILLION)
・     TABLE 31            WOUND CARE BIOLOGICS MARKET FOR DIABETIC FOOT ULCERS, BY REGION,  2021–2027 (USD MILLION)
7.2.2              VENOUS ULCERS
7.2.2.1            RISING PREVALENCE OF OBESITY TO DRIVE MARKET GROWTH
・     TABLE 32            WOUND CARE BIOLOGICS MARKET FOR VENOUS ULCERS, BY REGION,  2017–2020 (USD MILLION)
・     TABLE 33            WOUND CARE BIOLOGICS MARKET FOR VENOUS ULCERS, BY REGION,  2021–2027 (USD MILLION)
7.2.3              PRESSURE ULCERS   73
7.2.3.1            GROWING GERIATRIC POPULATION TO DRIVE MARKET GROWTH
・     TABLE 34            WOUND CARE BIOLOGICS MARKET FOR PRESSURE ULCERS, BY REGION,  2017–2020 (USD MILLION)
・     TABLE 35            WOUND CARE BIOLOGICS MARKET FOR PRESSURE ULCERS, BY REGION,  2021–2027 (USD MILLION)
7.2.4              OTHER ULCERS
・     TABLE 36            COMMERCIALLY AVAILABLE WOUND CARE BIOLOGIC PRODUCTS FOR OTHER ULCERS
・     TABLE 37            WOUND CARE BIOLOGICS MARKET FOR OTHER ULCERS, BY REGION, 
2017–2020 (USD MILLION)
・     TABLE 38            WOUND CARE BIOLOGICS MARKET FOR OTHER ULCERS, BY REGION, 
2021–2027 (USD MILLION)
7.3             SURGICAL & TRAUMATIC WOUNDS
7.3.1              RISING VOLUME OF SURGICAL PROCEDURES TO DRIVE MARKET GROWTH
・     TABLE 39            WOUND CARE BIOLOGICS MARKET FOR SURGICAL & TRAUMATIC WOUNDS, BY REGION, 2017–2020 (USD MILLION)
・     TABLE 40            WOUND CARE BIOLOGICS MARKET FOR SURGICAL & TRAUMATIC WOUNDS, BY REGION, 2021–2027 (USD MILLION)
7.4             BURNS
7.4.1              HIGH INCIDENCE OF BURN INJURIES IN EMERGING COUNTRIES TO DRIVE MARKET GROWTH
・     TABLE 41            WOUND CARE BIOLOGICS MARKET FOR BURNS, BY REGION,
2017–2020 (USD MILLION)
・     TABLE 42            WOUND CARE BIOLOGICS MARKET FOR BURNS, BY REGION,
2021–2027 (USD MILLION)

8      WOUND CARE BIOLOGICS MARKET, BY END USER

8.1             INTRODUCTION
・     TABLE 43            WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・     TABLE 44            WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
8.2             HOSPITALS
8.2.1              INCREASING NUMBER OF HOSPITALS & HIGH PATIENT INFLOW IN THIS CARE SETTING TO SUPPORT MARKET GROWTH
・     TABLE 45            WOUND CARE BIOLOGICS MARKET FOR HOSPITALS, BY REGION, 
2017–2020 (USD MILLION)
・     TABLE 46            WOUND CARE BIOLOGICS MARKET FOR HOSPITALS, BY REGION, 
2021–2027 (USD MILLION)
8.3             AMBULATORY SURGERY CENTERS
8.3.1              GROWING NUMBER OF SURGICAL PROCEDURES PERFORMED IN ASCS WILL ENSURE MARKET GROWTH IN THIS SEGMENT
・     TABLE 47            NUMBER OF BURN PATIENTS PER 1,000 ASC ADMISSIONS
・     TABLE 48            PRICE ASSESSMENT OF WOUND CARE BIOLOGICS IN AMBULATORY SURGERY CENTERS IN THE US
・     TABLE 49            WOUND CARE BIOLOGICS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2017–2020 (USD MILLION)
・     TABLE 50            WOUND CARE BIOLOGICS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021–2027 (USD MILLION)
8.4             BURN CARE CENTERS & WOUND CLINICS

8.4.1              RISING GERIATRIC POPULATION AND THE SUBSEQUENT INCREASE IN THE DEMAND FOR ASSISTED LIVING FACILITIES TO SUPPORT MARKET GROWTH
・     TABLE 51            WOUND CARE BIOLOGICS MARKET FOR BURN CARE CENTERS & WOUND CLINICS,  BY REGION, 2017–2020 (USD MILLION)
・     TABLE 52            WOUND CARE BIOLOGICS MARKET FOR BURN CARE CENTERS & WOUND CLINICS,  BY REGION, 2021–2027 (USD MILLION)

9      WOUND CARE BIOLOGICS MARKET, BY REGION

9.1             INTRODUCTION
・     TABLE 53            WOUND CARE BIOLOGICS MARKET, BY REGION, 2017–2020 (USD MILLION)
・     TABLE 54            WOUND CARE BIOLOGICS MARKET, BY REGION, 2021–2027 (USD MILLION)
9.2             NORTH AMERICA
・     FIGURE 19          NORTH AMERICA: WOUND CARE BIOLOGICS MARKET SNAPSHOT
・     TABLE 55            NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 
2017–2020 (USD MILLION)
・     TABLE 56            NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 
2021–2027 (USD MILLION)
・     TABLE 57            NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・     TABLE 58            NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 
2021–2027 (USD MILLION)
・     TABLE 59            NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2017–2020 (USD MILLION)
・     TABLE 60            NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2021–2027 (USD MILLION)
・     TABLE 61            NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 
2017–2020 (USD MILLION)
・     TABLE 62            NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.2.1              US
9.2.1.1            INCREASING PREVALENCE OF DIABETES AND NON-HEALING FOOT ULCERS TO SUPPORT THE UPTAKE OF WOUND BIOLOGICS PRODUCTS
・     TABLE 63            US: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・     TABLE 64            US: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・     TABLE 65            US: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・     TABLE 66            US: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・     TABLE 67            US: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・     TABLE 68            US: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.2.2              CANADA
9.2.2.1            RISING GERIATRIC PATIENT POOL TO DRIVE MARKET GROWTH FOR WOUND BIOLOGICS IN CANADA
・     TABLE 69            INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029
・     TABLE 70            CANADA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・     TABLE 71            CANADA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・     TABLE 72            CANADA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 
2017–2020 (USD MILLION)
・     TABLE 73            CANADA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 
2021–2027 (USD MILLION)
・     TABLE 74            CANADA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・     TABLE 75            CANADA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.3             EUROPE
・     TABLE 76            EUROPE: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2017–2020 (USD MILLION)
・     TABLE 77            EUROPE: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2021–2027 (USD MILLION)
・     TABLE 78            EUROPE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・     TABLE 79            EUROPE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・     TABLE 80            EUROPE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 
2017–2020 (USD MILLION)
・     TABLE 81            EUROPE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 
2021–2027 (USD MILLION)
・     TABLE 82            EUROPE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・     TABLE 83            EUROPE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.3.1              UK
9.3.1.1            INCREASING INCIDENCE OF VENOUS ULCERS TO DRIVE THE MARKET GROWTH
・     TABLE 84            UK: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・     TABLE 85            UK: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・     TABLE 86            UK: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・     TABLE 87            UK: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・     TABLE 88            UK: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・     TABLE 89            UK: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.3.2              GERMANY
9.3.2.1            THE LARGE DIABETIC POPULATION IN GERMANY SUPPORTS THE UPTAKE OF WOUND BIOLOGICS IN GERMANY
・     TABLE 90            GERMANY: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・     TABLE 91            GERMANY: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・     TABLE 92            GERMANY: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 
2017–2020 (USD MILLION)
・     TABLE 93            GERMANY: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 
2021–2027 (USD MILLION)
・     TABLE 94            GERMANY: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・     TABLE 95            GERMANY: WOUND CARE BIOLOGICS MARKET, BY END USER, 
2021–2027 (USD MILLION)
9.3.3              FRANCE
9.3.3.1            RISING GOVERNMENT SUPPORT TO DRIVE THE DEMAND FOR WOUND CARE BIOLOGICS PRODUCTS IN FRANCE
・     TABLE 96            FRANCE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・     TABLE 97            FRANCE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・     TABLE 98            FRANCE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・     TABLE 99            FRANCE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 
2021–2027 (USD MILLION)
・     TABLE 100          FRANCE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・     TABLE 101          FRANCE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.3.4              REST OF EUROPE
・     TABLE 102          ROE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・     TABLE 103          ROE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・     TABLE 104          ROE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・     TABLE 105          ROE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・     TABLE 106          ROE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・     TABLE 107          ROE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.4             ASIA PACIFIC
・     FIGURE 20          ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET SNAPSHOT
・     TABLE 108          ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 
2017–2020 (USD MILLION)
・     TABLE 109          ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 
2021–2027 (USD MILLION)
・     TABLE 110          ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 
2017–2020 (USD MILLION)
・     TABLE 111          ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・     TABLE 112          ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 
2017–2020 (USD MILLION)
・     TABLE 113          ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 
2021–2027 (USD MILLION)
・     TABLE 114          ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・     TABLE 115          ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY END USER, 
2021–2027 (USD MILLION)
9.4.1              CHINA
9.4.1.1            INCREASING INCIDENCE OF DFUS TO PROPEL THE MARKET GROWTH
・     TABLE 116          CHINA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・     TABLE 117          CHINA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・     TABLE 118          CHINA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・     TABLE 119          CHINA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・     TABLE 120          CHINA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・     TABLE 121          CHINA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.4.2              JAPAN
9.4.2.1            GROWING GERIATRIC POPULATION TO DRIVE THE ADOPTION OF WOUND CARE PRODUCTS
・     TABLE 122          JAPAN: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・     TABLE 123          JAPAN: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・     TABLE 124          JAPAN: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・     TABLE 125          JAPAN: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・     TABLE 126          JAPAN: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・     TABLE 127          JAPAN: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.4.3              INDIA
9.4.3.1            GROWING MEDICAL TOURISM IN THE COUNTRY TO SUPPORT THE MARKET GROWTH FOR WOUND BIOLOGICS
・     TABLE 128          INDIA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・     TABLE 129          INDIA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・     TABLE 130          INDIA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・     TABLE 131          INDIA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・     TABLE 132          INDIA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・     TABLE 133          INDIA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.4.4              REST OF ASIA PACIFIC
・     TABLE 134          ROAPAC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・     TABLE 135          ROAPAC WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・     TABLE 136          ROAPAC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 
2017–2020 (USD MILLION)
・     TABLE 137          ROAPAC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 
2021–2027 (USD MILLION)
・     TABLE 138          ROAPAC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・     TABLE 139          ROAPAC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.5             LATIN AMERICA
9.5.1              RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT THE MARKET GROWTH
・     TABLE 140          LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 
2017–2020 (USD MILLION)
・     TABLE 141          LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 
2021–2027 (USD MILLION)
・     TABLE 142          LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2017–2020 (USD MILLION)
・     TABLE 143          LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2021–2027 (USD MILLION)
・     TABLE 144          LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 
2017–2020 (USD MILLION)
・     TABLE 145          LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 
2021–2027 (USD MILLION)
9.6             MIDDLE EAST & AFRICA
9.6.1              SIGNIFICANT GROWTH IN HEALTHCARE INFRASTRUCTURE TO DRIVE THE MARKET GROWTH FOR WOUND BIOLOGICS
・     TABLE 146          MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,  2017–2020 (USD MILLION)
・     TABLE 147          MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,  2021–2027 (USD MILLION)
・     TABLE 148          MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2017–2020 (USD MILLION)
・     TABLE 149          MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,  2021–2027 (USD MILLION)
・     TABLE 150          MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY END USER,  2017–2020 (USD MILLION)
・     TABLE 151          MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY END USER,  2021–2027 (USD MILLION)

10   COMPETITIVE LANDSCAPE

10.1          OVERVIEW
10.2          KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1            OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE WOUND CARE BIOLOGICS MARKET
・     TABLE 152          OVERVIEW OF STRATEGIES DEPLOYED BY KEY WOUND CARE BIOLOGICS MANUFACTURING COMPANIES
10.3          MARKET SHARE ANALYSIS
10.3.1            WOUND CARE BIOLOGICS MARKET
・     FIGURE 21          WOUND CARE BIOLOGICS MARKET SHARE, BY KEY PLAYER (2021)
・     TABLE 153          WOUND CARE BIOLOGICS MARKET: DEGREE OF COMPETITION
10.4          COMPANY EVALUATION QUADRANT
10.4.1            LIST OF EVALUATED VENDORS
10.4.2            STARS
10.4.3            EMERGING LEADERS
10.4.4            PERVASIVE PLAYERS
10.4.5            PARTICIPANTS
・     FIGURE 22          WOUND CARE BIOLOGICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
10.5          COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
10.5.1            PROGRESSIVE COMPANIES
10.5.2            STARTING BLOCKS   136
10.5.3            RESPONSIVE COMPANIES
10.5.4            DYNAMIC COMPANIES   136
・     FIGURE 23          WOUND CARE BIOLOGICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
10.6          COMPETITIVE SCENARIO   137
10.6.1            PRODUCT LAUNCHES & REGULATORY APPROVALS
・     TABLE 154          KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
10.6.2            DEALS
・     TABLE 155          KEY DEALS
10.6.3            OTHER DEVELOPMENTS
・     TABLE 156          OTHER DEVELOPMENTS

11   COMPANY PROFILES

11.1          KEY PLAYERS
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW, KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESS AND COMPETITIVE THREATS)*
11.1.1            SMITH & NEPHEW PLC
・     TABLE 157          SMITH & NEPHEW PLC: BUSINESS OVERVIEW
・     FIGURE 24          SMITH & NEPHEW PLC: COMPANY SNAPSHOT (2021)
11.1.2            ORGANOGENESIS INC.
・     TABLE 158          ORGANOGENESIS INC.: BUSINESS OVERVIEW
・     FIGURE 25          ORGANOGENESIS INC.: COMPANY SNAPSHOT (2021)
11.1.3            MIMEDX
・     TABLE 159          MIMEDX: BUSINESS OVERVIEW
・     FIGURE 26          MIMEDX: COMPANY SNAPSHOT (2021)
11.1.4            INTEGRA LIFESCIENCES
・     TABLE 160          INTEGRA LIFESCIENCES: BUSINESS OVERVIEW
・     FIGURE 27          INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2021)
11.1.5            STRYKER CORPORATION
・     TABLE 161          STRYKER CORPORATION: BUSINESS OVERVIEW
・     FIGURE 28          STRYKER CORPORATION: COMPANY SNAPSHOT (2021)
11.1.6            MÖLNLYCKE HEALTH CARE AB
・     TABLE 162          MÖLNLYCKE HEALTH CARE AB: BUSINESS OVERVIEW
・     FIGURE 29          MÖLNLYCKE HEALTH CARE AB: COMPANY SNAPSHOT (2021)
11.1.7            VERICEL CORPORATION
・     TABLE 163          VERICEL CORPORATION: BUSINESS OVERVIEW
・     FIGURE 30          VERICEL CORPORATION: COMPANY SNAPSHOT (2021)
11.1.8            ANIKA THERAPEUTICS, INC.
・     TABLE 164          ANIKA THERAPEUTICS, INC.: BUSINESS OVERVIEW
・     FIGURE 31          ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2021)
11.1.9            BIOVENTUS LLC
・     TABLE 165          BIOVENTUS LLC: BUSINESS OVERVIEW
・     FIGURE 32          BIOVENTUS LLC: COMPANY SNAPSHOT (2021)
11.1.10         ABBVIE INC.
・     TABLE 166          ABBVIE INC.: BUSINESS OVERVIEW
・     FIGURE 33          ABBVIE INC.: COMPANY SNAPSHOT (2021)
11.1.11         KERECIS
・     TABLE 167          KERECIS: BUSINESS OVERVIEW    165
11.1.12         MARINE POLYMER TECHNOLOGIES, INC.
・     TABLE 168          MARINE POLYMER TECHNOLOGIES, INC.: BUSINESS OVERVIEW
11.2          OTHER PLAYERS
11.2.1            MERAKRIS THERAPEUTICS
・     TABLE 169          MERAKRIS THERAPEUTICS: COMPANY OVERVIEW
11.2.2            POLYMEDICS INNOVATIONS GMBH
・     TABLE 170          POLYMEDICS INNOVATIONS GMBH: COMPANY OVERVIEW
11.2.3            FIBROHEAL WOUNDCARE PVT. LTD.
・     TABLE 171          FIBROHEAL WOUNDCARE PVT. LTD.: COMPANY OVERVIEW
11.2.4            ANAMAY BIOTECH, INC.
・     TABLE 172          ANAMAY BIOTECH, INC.: COMPANY OVERVIEW
11.2.5            VIRCHOW BIOTECH PRIVATE LIMITED
・     TABLE 173          VIRCHOW BIOTECH PRIVATE LIMITED: COMPANY OVERVIEW
11.2.6            MEDLINE INDUSTRIES, LP
・     TABLE 174          MEDLINE INDUSTRIES, LP: COMPANY OVERVIEW
11.2.7            TIDES MEDICAL
・     TABLE 175          TIDES MEDICAL: COMPANY OVERVIEW
11.2.8            VISCUS BIOLOGICS LLC
・     TABLE 176          VISCUS BIOLOGICS LLC: COMPANY OVERVIEW
11.2.9            STABILITY BIOLOGICS
・     TABLE 177          STABILITY BIOLOGICS: COMPANY OVERVIEW
11.2.10         MTF BIOLOGICS
・     TABLE 178          MTF BIOLOGICS: COMPANY OVERVIEW
11.2.11         SKYE BIOLOGICS HOLDINGS, LLC
・     TABLE 179          SKYE BIOLOGICS HOLDINGS, LLC: COMPANY OVERVIEW
11.2.12         ALLOSOURCE
・     TABLE 180          ALLOSOURCE: COMPANY OVERVIEW    172
11.2.13         SURGILOGIX
・     TABLE 181          SURGILOGIX: COMPANY OVERVIEW    173
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW, KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESS AND COMPETITIVE THREATS MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
12   APPENDIX


△ 一番上に戻る